Localized Prostate Cancer, Prostate Cancer
Conditions
Keywords
prostate cancer, prostatectomy, localized prostate cancer
Brief summary
This study investigates the pathologic effects of the combination of enzalutamide, abiraterone acetate, dutasteride, and degarelix when given for 12 weeks prior to prostatectomy in men with localized prostate cancer. Enzalutamide, an androgen receptor (AR) antagonist, blocks binding of testosterone to the AR as well as preventing nuclear translocation of the AR and DNA binding. Abiraterone acetate inhibits the CYP17 pathway, which is involved in the formation of androgens. Dutasteride is a 5-alpha-reductase inhibitor which blocks conversion of testosterone to dihydrotestosterone. Degarelix, a gonadotropin-releasing hormone (GnRH) antagonist, binds to GnRH receptors on the pituitary gland thus suppressing testosterone release from the testes. Therefore it is hypothesized that the combination of enzalutamide, abiraterone acetate, dutasteride, and degarelix will result in near-complete AR inhibition and produce favorable pathologic changes after 12 weeks of therapy.
Interventions
DRUGEnzalutamide
160mg
DRUGAbiraterone acetate
1000mg
DRUGPrednisone
5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
DRUGDutasteride
0.5mg
DRUGDegarelix
240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
Sponsors
Prostate Cancer Foundation Norway
Kenneth Pienta, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Willing and able to provide written informed consent. 2. Age ≥ 18 years 3. Eastern cooperative group (ECOG) performance status ≤2 4. Documented histologically confirmed adenocarcinoma of the prostate 5. Willing to undergo prostatectomy as primary treatment for localized prostate cancer 6. High risk prostate cancer (per NCCN criteria): Gleason score 8-10 or T3a or PSA \> 20 ng/mL -Or- Very-high risk prostate cancer (per NCCN criteria): T3b -T4 7. Serum testosterone ≥150 ng/dL 8. Able to swallow the study drugs whole as tablets 9. Willing to take abiraterone acetate on an empty stomach (no food should be consumed at least two hours before and for one hour after dosing). 10. Willing to use a condom if having sex with a pregnant woman, or use a condom and another effective method of birth control if having sex with a woman of child-bearing potential. These measures are required during and for one week after treatment with abiraterone.
Exclusion criteria
1. Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy) 2. Prior use of enzalutamide or abiraterone acetate 3. Prior or ongoing systemic therapy for prostate cancer including, but not limited to: 1. Hormonal therapy (e.g. leuprolide, goserelin, triptorelin, degarelix) 2. CYP-17 inhibitors (e.g. ketoconazole) 3. Antiandrogens (e.g. bicalutamide, nilutamide) 4. Second generation antiandrogens (e.g. enzalutamide, ARN-509) 5. Immunotherapy (e.g. sipuleucel-T, ipilimumab) 6. Chemotherapy (e.g. docetaxel, cabazitaxel) 4. Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition (including laboratory abnormalities) that could interfere with patient safety or provision of informed consent to participate in this study. 5. Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule. 6. Abnormal bone marrow function \[absolute neutrophil count (ANC)\<1500/mm3, platelet count \<100,000/mm3, hemoglobin \<9 g/dL\] 7. Abnormal liver function (bilirubin, AST, ALT ≥ 3 x upper limit of normal) 8. Abnormal kidney function (serum creatinine ≥ 2 x upper limit of normal) 9. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III or IV heart failure or history of a prior myocardial infarction (MI) within the last five years prior to enrollment in the study. 10. History of prior cardiac arrhythmia.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of prostatectomy specimens with a complete response rate | 12 weeks | Proportion of prostatectomy specimens with complete response rate after 12 weeks of therapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of prostatectomy specimens with a near-pathologic complete response | 12 weeks | Proportion of prostatectomy specimens with a near-pathologic complete response (\<=5mm of residual tumor) after 12 weeks of therapy |
| Proportion of prostatectomy specimens with pathologic T3 disease | 12 weeks | Proportion of prostatectomy specimens with pathologic T3 disease after 12 weeks of therapy |
| Change in immunologic parameters (TREC levels and antibody responses) | 16 weeks | Change in immunologic parameters (TREC levels and antibody responses) after 12 weeks of enzalutamide, abiraterone acetate, dutasteride and degarelix and an additional month of degarelix monotherapy (16 weeks total). |
| Proportion of radiographic disappearance of MRI detectable significant prostate nodules | 12 weeks | Proportion of radiographic disappearance of MRI detectable significant prostate nodules after 12 weeks of therapy. |
| Proportion of prostatectomy specimens with a negative surgical margin rate | 12 weeks | Proportion of prostatectomy specimens with a negative surgical margin rate after 12 weeks of therapy |
| PSA progression free survival | 2 years after last accrual | The biochemical (i.e. PSA) progression free survival estimate two years after the last patient has accrued. |
| Overall survival | 2 years after last accrual | The overall survival estimate two years after the last patient has accrued. |
| Incidence and severity of adverse events | 16 weeks | Safety as assessed by the incidence and severity of adverse events and serious adverse events graded according to the National Cancer Institute - Common Terminology Criteria for adverse events (CTCAE) version 4.0 |
| Exploratory biomarkers assessment | 16 weeks | Exploratory biomarker Assessment. Examples of these may include, but are not limited to: assessment for genomic PTEN loss via fluorescence in situ hybridization (FISH), PTEN immunohistochemistry (IHC), assessment for alteration in MYC/chromosome 8q24 via FISH, RNAseq analysis, serum drug/androgen levels and intraprostatic drug/androgen levels. |
| Proportion of men who receive adjuvant radiation therapy within 1 year of prostatectomy | 64 weeks | Proportion of men who receive adjuvant radiation therapy within 1 year of prostatectomy (12 weeks of therapy + 1 year = 64 weeks) |
Countries
United States
Outcome results
None listed